925206-65-1

Basic information

• Product Name: RRX-001
• Synonyms: RRX-001;2-bromo-1-(3,3-dinitroazetidin-1-yl)ethan-1-one
• CAS NO: 925206-65-1
• Molecular Formula: C5H6BrN3O5
• Molecular Weight: 268.02224
• Mol File: 925206-65-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 473.0±45.0 °C(Predicted)
• Appearance: /
• Density: 1.98±0.1 g/cm3(Predicted)
• PKA: -2.07±0.20(Predicted)
• CAS DataBase Reference: RRX-001(CAS DataBase Reference)
• NIST Chemistry Reference: RRX-001(925206-65-1)
• EPA Substance Registry System: RRX-001(925206-65-1)

Safety Data

• Hazardous Substances Data: 925206-65-1(Hazardous Substances Data)

Usage

General Description

RRX-001 is a novel small molecule with potential anticancer properties. It works by selectively targeting and altering the tumor microenvironment, making it more susceptible to chemotherapy and radiation treatments. RRX-001 acts by increasing the levels of nitric oxide (NO) and reactive oxygen species (ROS) within the tumor, which weakens the cancer cells and enhances the effectiveness of traditional cancer therapies. Additionally, RRX-001 has the ability to inhibit angiogenesis, the process by which tumors form new blood vessels to thrive and metastasize. Overall, RRX-001 has shown promising results in preclinical and clinical studies and has the potential to improve treatment outcomes for cancer patients.

Upstream product

• 125735-38-8 N-tert-butyl-3,3-dinitroazetidine 
• 598-21-0 2-Bromoacetyl bromide 

Downstream Products

• 1429643-39-9 (R)-methyl 2-acetamido-3-(2-(3,3-dinitroazetidin-1-yl)-2-oxoethylthio)propanoate 

Relevant articles and documents

Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development

After extensive screening of aerospace compounds in an effort to source a novel anticancer agent, RRx-001, a first-in-class dinitroazetidine small molecule, was selected for advancement into preclinical and clinical development. RRx-001 is a minimally tox

METHODS OF SYNTHESIZING AND ISOLATING N-(BROMOACETYL)-3,3-DINITROAZETIDINE AND A COMPOSITION INCLUDING THE SAME

A method of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine (ABDNAZ) by reacting DNAZ with bromoacetyl bromide and boron trifluoride etherate to produce a mixture comprising ABDNAZ and a salt of DNAZ. Water and a solvent are added to the mixture to form an organic phase comprising the ABDNAZ and an aqueous phase comprising the salt of DNAZ. The organic phase and the aqueous phase are separated to produce an ABDNAZ/solvent solution comprising the ABDNAZ and the aqueous phase comprising the salt of DNAZ. A nonsolvent is added to the ABDNAZ/solvent solution to produce an ABDNAZ/solvent/nonsolvent mixture. The ABDNAZ is subsequently recovered. A composition comprising ABDNAZ is also disclosed.